✦ LIBER ✦

S1049 Socioeconomic Disparities in Patients with Metastatic Gastrointestinal Stromal Tumors: Imatinib and the Shift Toward Equality

✍ Scribed by Avo Artinyan; Joseph Kim; Perry Soriano; Smita Bhatia; Joshua Ellenhorn

Book ID: 119428646
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 69 KB
Volume: 134
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(08)60773-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Resection of residual disease in patient

Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib

✍ Sebastian Bauer; Jörg Thomas Hartmann; Maike de Wit; Hauke Lang; Florian Grabell 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 723 KB

## Abstract Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. Long‐term survival of patients with metastatic disease has only been observed in patients with completely resected disease. Recently, the tyrosine kinase inhibitor imatinib has b

Phase I study of panobinostat and imatin

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

✍ Bauer, S; Hilger, R A; Mühlenberg, T; Grabellus, F; Nagarajah, J; Hoiczyk, M; Re 📂 Article 📅 2014 🏛 Nature Publishing Group 🌐 English ⚖ 506 KB

Patterns of Care, Prognosis, and Surviva

Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib

✍ Antoine Italiano; Angela Cioffi; Paola Coco; Robert G. Maki; Patrick Schöffski; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 384 KB

Evaluation of Self-Reported Progression

Evaluation of Self-Reported Progression and Correlation of Imatinib Dose to Survival in Patients with Metastatic Gastrointestinal Stromal Tumors: An Open Cohort Study

✍ Jerry Call; Norman J. Scherzer; P. David Josephy; Christopher Walentas 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 232 KB

Imatinib plus low-dose doxorubicin in pa

Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib : A phase I-II study by the Spanish group for research on sarcomas

✍ Joan Maurel; Ana Sofia Martins; Andrés Poveda; José Antonio López-Guerrero; Rica 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 403 KB 👁 3 views

212 POSTER A phase II study of the KIT i

212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib

✍ A.J. Wagner; S. Yazji; J.A. Morgan; E. Choy; S. George; M. Hohos; M. O'Mara; G.D 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 59 KB